Amylyx Pharmaceuticals, Inc./$AMLX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
- Ticker
- $AMLX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 136
- Headquarters
- Cambridge, United States
- Website
- amylyx.com
AMLX Metrics
BasicAdvanced
$3.3B
-
-$1.43
-0.12
-
Price and volume
Market cap
$3.3B
Beta
-0.12
52-week high
$41.14
52-week low
$10.83
Average daily volume
1.4M
Financial strength
Current ratio
12.12
Quick ratio
12.45
Long term debt to equity
0.022
Total debt to equity
0.022
Profitability
EBITDA (TTM)
-161.734
Effective tax rate (TTM)
-0.03%
Management effectiveness
Return on assets (TTM)
-44.13%
Return on equity (TTM)
-74.73%
Valuation
Price to book
12.27
Price to tangible book (TTM)
12.27
Price to free cash flow (TTM)
-21.418
Free cash flow yield (TTM)
-4.67%
Free cash flow per share (TTM)
-1.23
Growth
Earnings per share change (TTM)
-40.59%
3-year earnings per share growth (CAGR)
8.23%
What the Analysts think about AMLX
Analyst ratings (Buy, Hold, Sell) for Amylyx Pharmaceuticals, Inc. stock.
Analyst projections of the future price of Amylyx Pharmaceuticals, Inc. stock.
Bulls say / Bears say
Avexitide delivered a clear late-stage result: Phase 3 LUCIDITY reported a 55% reduction in the combined rate of Level 2 and Level 3 hypoglycaemic events versus placebo, meeting its primary endpoint. This materially strengthens Amylyx’s lead programme. (SEC)
There is no FDA-approved treatment for post-bariatric hypoglycaemia, giving avexitide a potential first-mover opportunity. Amylyx plans to file an NDA by the end of 2026 and is preparing for a possible 2027 launch. (SEC, Amylyx Pharmaceuticals)
Amylyx also has potential beyond avexitide: AMX0035 showed encouraging signs of stabilisation or improvement in a small Wolfram syndrome study, and the company is working with the FDA on a Phase 3 trial. Success there could broaden its longer-term pipeline opportunity. (Amylyx Pharmaceuticals, Amylyx Pharmaceuticals)
The LUCIDITY result comes from a 78-person trial with a 16-week double-blind treatment period, and the company has so far reported topline results. The small study and limited blinded follow-up leave uncertainty about how robust and durable the benefit will be. (SEC)
Reported supply agreements include minimum purchase commitments and a $30 million capacity fee from 2028. If uptake or pricing is weaker than hoped, these fixed costs could weigh on the economics of a launch. (Simply Wall St)
Amylyx proposed a $350 million share offering after the Phase 3 result to fund pre-commercial preparations. The capital may support a launch, but issuing shares dilutes existing investors. (Allsci)
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2026.
AMLX Financial Performance
Revenues and expenses
AMLX Earnings Performance
Company profitability
Upcoming events
No upcoming events
AMLX News
AllArticlesVideos
Funds containing AMLX
AllUSDGBPEUR
Fund name | Fund size | $AMLX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.23% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.23% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.16% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.